Of interest in a recent systematic review of predictors of response to biologic therapy in RA, conflicting results were reported for FCGR variants and no association between RTX responses and IL-6 promoter 174 were observed [38]. This evidence concerns the gene FCGR2A and rheumatoid arthritis.